Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) confirmed on Thursday that it has completed the acquisition of Yellow Jersey Therapeutics for USD1.25bn.
Through this transaction J&J secures the global rights to NM26, a Phase 2-ready bispecific antibody targeting two pathways in atopic dermatitis.
NM26 targets IL-4R alpha subunit and IL-31, which trigger skin inflammation and itch. Atopic dermatitis is a common inflammatory skin disease causing itching, inflammation and increased risk of infections.
J&J aims to expand its treatment options for atopic dermatitis and other immune-mediated diseases.
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Pfizer names new Regional President for Middle East, Russia and Africa
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lipella launches OLP Patient Registry to advance research
Talphera enrols first subject in NEPHRO CRRT study
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Cantargia reports positive CAN10 trial data
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development